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Abstract
Background: Interleukin-5 (IL-5) is thought to play a pivotal role in the pathogenesis of asthma.
High levels of circulating IL-5 have been documented in acute asthma. However, serum IL-5 levels
in mild to moderate asthmatics and the influence of regular use of inhaled glucocorticoids, is not
known.
Methods: Fifty-six asthmatics and 56 age and sex matched controls were recruited prospectively
from an outpatient department. Information on asthma severity and treatment was gathered by a
questionnaire. Serum IL-5, total IgE and specific IgE levels were measured in a blinded fashion.
Results: There were 32 atopic and 24 non-atopic mild-to-moderate asthmatics. The median serum
IL-5 levels in atopic asthmatics (9.5 pg/ml) and in non-atopic asthmatics (8.1 pg/ml) were significantly
higher than in normal controls (4.4 pg/ml, both p < 0.003). However, median serum IL-5 levels in
atopic and non-atopic asthmatics were not significantly different. The median serum IL-5 level was
insignificantly higher in fourteen moderate persistent asthmatics (10.6 pg/ml) compared to forty-
two mild persistent asthmatics (7.3 pg/ml) (p = 0.13). The median serum IL-5 levels in asthmatics
using regular inhaled steroids (7.8 pg/ml) was not significantly different from those not using inhaled
steroids (10.2 pg/ml). Furthermore, serum total IgE levels and eosinophil counts were not
significantly different in those using versus those not using inhaled glucocorticoids.
Conclusion: Serum IL-5 levels are elevated in mild and moderate persistent atopic and non-atopic
asthmatics. Regular use of inhaled glucocorticoids may not abrogate the systemic Th2 type of
inflammatory response in mild-moderate persistent asthma.
Background
The vast majority of patients with asthma exhibit mild or
moderate states of clinical severity [1]. Interleukin-5 (IL-
5) plays a pivotal role in the pathogenesis of airway
inflammation in asthma [2-5]. Although activated CD3+
T cells are the primary source of IL-5 in atopic asthma,
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CD8 cells are thought to be the main source in non-atopic
asthma [6]. A reduction in IL-5 induced eosinophilia
upon subcutaneous administration of glucocorticoids in
an animal model of asthma, has been documented by
Wada and associates [7]. Furthermore, oral glucocorti-
coids have been shown to reduce elevated serum IL-5 lev-
els in patients with acute asthma [8]. Visser and associates
attempted to measure serum IL-5 levels in children on
inhaled steroids [9]. However, the assay could not detect
serum IL-5 levels in 45% of asthmatics. To our knowledge,
the single report in the literature on serum IL-5 levels in
adult asthmatics on inhaled glucocorticoids studied a
small group of patients (14 atopic asthmatics) whose
asthma severity was not graded [10]. Therefore, we set up
this prospective cross sectional study to document serum
IL-5 levels in an adult population of atopic and non-
atopic asthmatics with mild and moderate persistent
asthma, approximately half of these patients were receiv-
ing regular treatment with inhaled glucocorticoids.
Methods
Stable asthmatics attending the outpatient department of
a university hospital between January 2001 and May 2002
were recruited in this prospective study. Fifty-six patients
(15 males, 41 females, aged 18 – 55 years) with a clinical
diagnosis of asthma according to the Expert Panel Report
2 [11] were studied. Exclusion criteria included preg-
nancy, a positive history of smoking and treatment with
oral glucocorticoids, anti leukotreines, theophyllines or
antihistamines within 4 weeks of the study. Patients
receiving medication for any other condition were also
excluded. The institutional research ethics committee
approved the study protocol. After obtaining informed
written consent, details of asthma symptoms and treat-
ment, especially inhaled glucocorticoid usage, were col-
lected using a pre-designed questionnaire.
Patients were classified as atopic if one or more specific
IgE tests were positive to the common allergens prevalent
locally. Furthermore, study patients were classified into
one of three asthma subgroups: mild intermittent, mild
persistent or moderate persistent using a modification of
the clinical criteria proposed by the NIH [11] as peak flow
variability data was not available in this cross-sectional
study. Of the 56 patients, 31 had not received inhaled glu-
cocorticoids at least 12 months prior to the study, of
which, two patients reported infrequent usage of inhaled
glucocorticoids two weeks prior to recruitment. Twenty-
five patients reported regular use of inhaled glucocorti-
coids prior to recruitment to the study. Among the 25 reg-
ularly using inhaled glucocorticoids, 20 reported usage for
at least 12 months, four for 9 months and one for 3
months. The type of inhaled glucocorticoids, was Flutica-
sone 500 microgram twice daily in 19 patients and
Budosenide 400 microgram twice daily in six patients.
Healthy adults between the ages 18 and 55 years, matched
for age and sex were recruited as normal controls. Exclu-
sion criteria for normal controls were: history of child-
hood asthma, a family history of asthma, a febrile illness
or chest infection within the previous four weeks, or epi-
sodes of cough and wheezing in the past 12 months.
Finally, individuals with a serum total IgE value of ≥120
IU/L were excluded from the control group. Upon recruit-
ment, a forearm venous blood was drawn from all study
subjects for complete blood count and cytokine
estimation.
Serum total IgE and specific IgE estimation
Blood samples for total IgE and IL-5 estimation were col-
lected in plain vacutainers and the serum separated and
stored at -80°C until assayed. Total serum IgE was meas-
ured by a Microparticle Enzyme Immunoassay (IMx Total
IgE Assay, Abbott Laboratories, IL, USA). Serum-specific
IgE to six common allergens (House dust mite-Dermat-
ophagoides pteronyssinus and Dermatophagoides fari-
nae, Bermuda grass, mesquite, cockroach and Aspergillus
fumigatus) were measured using ImmunoCAP technol-
ogy (Pharmacia Upjohn Diagnostics, Uppsala, Sweden).
The complete blood count was documented using a Coul-
ter counter.
Measurement of serum levels of interleukin-5
IL-5 was measured using a specific enzyme linked immu-
noassay (BioSource, Camarillo, CA). This assay has been
calibrated against the WHO reference preparation 90/586
(NIBSC, Hertfordshire, UK). The IL-5 standard curve was
constructed using serial dilutions (750,375,187.5,93.7,
46.8,23.4, 11.7, and 0 pg/ml) of standard IL-5. A curve-fit-
ting software program was used to quantitate IL-5 concen-
trations. The minimum level of detection of IL-5 with this
ELISA was 2 pg/ml. The intra-assay coeffieient of variation
was 7.4% and the inter-assay coefficient of variation was
10%. All assays were performed by technical staff who
were blinded to patients groupings.
Statistical analysis
Data were analyzed using computer software SPSS. All
continuous variables not normally distributed, were com-
pared using the Kruskal-Wallis test. The Mann-Whitney
test was used for multiple pair-wise comparisons and
Bonferroni correction applied for the final p value. Asso-
ciations between duration of asthma and serum IL-5 were
estimated using Spearman's rank correlation. A p value of
< 0.05 was considered statistically significant.
Results
Table 1 shows the age, sex and pertinent laboratory values
among study subjects. Of the fifty-six asthmatics, 32 were
atopic and 24 non-atopic. Asthma severity was mild-inter-
mittent in 4 patients, mild-persistent in 38 and moderate-BMC Pulmonary Medicine 2004, 4 http://www.biomedcentral.com/1471-2466/4/2
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persistent in 14. As there were only 4 mild-intermittent
patients, they were combined with the mild-persistent
group for statistical analysis. Of the 56 asthmatics, 25
reported regular use of inhaled glucocorticoids. Figure 1
shows the median and inter-quartile range (IQR) values
of serum IL-5 levels in asthmatics and normal controls.
The median serum IL-5 levels varied significantly between
atopic, non-atopic asthmatics and controls (p < 0.001).
The serum IL-5 levels (median, IQR) in atopic asthmatics
(9.57 pg/ml, 3.74–15.64) and in non-atopic asthmatics
(8.17 pg/ml, 4.21–15.47) were significantly higher com-
pared to normal controls (4.4 pg/ml, 2.99–6.51) (both p
= 0.003). However, the median serum IL-5 levels in atopic
and non-atopic asthmatics were not significantly
different.
Figure 2 illustrates serum IL-5 levels in mild-persistent
and moderate-persistent asthmatics and controls. Of the
42 mild persistent asthmatics, 22 were atopic and 20 non-
atopic. In the moderate persistent group 10 were atopics
and 4 were non-atopic. The median serum IL-5 level was
insignificantly higher in fourteen moderate persistent
asthmatics (10.61 pg/ml, 7.34 – 26.6) compared to forty-
two mild persistent asthmatics (7.3 pg/ml, 3.56 – 15.41)
(p = 0.13). Whereas median serum IL-5 levels in mild per-
sistent asthmatics and moderate-persistent asthmatics
were significantly higher than in controls (both p= 0.003).
Figure 3 shows serum IL-5 levels in asthmatics using regu-
lar inhaled glucocorticoids, in those not using inhaled
glucocorticoids and in normal controls. The median
serum IL-5 levels in asthmatics using regular inhaled ster-
oids (10.29 pg/ml, 4.96–14.55) was not significantly dif-
ferent compared to those not using inhaled steroids (7.81
pg/ml, 3.69–15.92). However, the serum IL-5 levels were
significantly higher in asthmatics on inhaled steroids and
not on inhaled steroids compared with controls (4.43 pg/
ml, 2.99–6.51, p < 0.003 and < 0.006 respectively).
There was no significant correlation between the duration
of asthma in years and levels of serum IL-5 in asthmatics
(r = 0.04). Also, there was no significant correlation
between serum IL-5 levels and absolute eosinophil
counts, serum total IgE or FEV1 in asthmatics.
Discussion
IL-5 has been clearly implicated as an important cytokine
mediating airway inflammation in both atopic and non-
atopic types of asthma [12-14]. Elevated serum IL-5 levels
Table 1: Clinical & laboratory parameters in study subjects
Normal Control (n = 56) Asthmatics (n = 56) P value
On Inhaled Steroids (n = 31) Not on Inhaled Steroids (n = 25)
Age (years) 27 (22–39) 27 (23–38) 28 (21–40) 0.6*
Duration of asthma (years) - 5 (1–15) 10 (4.5–14.5) 0.18*
Atopic asthma - 16 16 0.42 †
Non-atopic asthma - 9 15
FEV1 (liter) - 2.3 (2–2.67) 2 (1.7–2.5) 0.2*
WBC count (× 109/L) 6.5 (5.1–7.5) 6.4 (5.1–8.3) 6 (5.1–8.1) 0.8*
Eosinophils % 0.11(0.07–0.18) 5 (2–9) 6 (4–10) 0.2*
Serum IgE (IU/L) 26 (10–62) 240 (54–595) 200 (96–612) 0.8*
Data are expressed as medians with interquartile range in parenthesis * By Mann Whitney test between steroid and non-steroid users † By Fisher's 
exact test between steroid and non-steroid users
Serum IL-5 levels according to the type of asthma Figure 1
Serum IL-5 levels according to the type of asthma. The box & 
whisker plot shows the median and interquartile values of 
serum IL-5 levels. Although the median serum Il-5 value in 
atopic and non-atopic groups were significantly higher com-
pared to normal controls, there was no significant difference 
in the median serum IL-5 level between atopic and non-
atopic groupsBMC Pulmonary Medicine 2004, 4 http://www.biomedcentral.com/1471-2466/4/2
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in atopic and non-atopic asthmatics as compared with
normal controls in the present study, support this hypoth-
esis. Serum IL-5 levels in atopic and non-atopic asthmat-
ics were not significantly different. Contrary to a previous
study by Alexander and associates [15], we were able to
detect serum IL-5 levels in both controls and asthmatic
patients using an assay with increased sensitivity.
Whereas interleukin-5 levels are shown to be elevated in
acute asthma, this is the first demonstration that levels are
also elevated  in less-severe asthmatics who represent the
vast majority of patients. There was a tendency for serum
IL-5 levels to be higher in moderate persistent asthmatics
compared to mild persistent asthmatics. A previous study
reported that systemic IL-5 levels were elevated in acute
severe asthmatics but were significantly reduced following
treatment with oral glucocorticoids. However, the serum
IL-5 levels remained above levels observed in normal con-
trols [8]. Our observation of raised serum IL-5 levels in a
different and more common subgroup i.e. in mild and
moderate persistent asthmatics using regular inhaled glu-
cocorticoids, is consistent with this report.
Our finding, for the first time, that regular use of inhaled
glucocorticoids fails to normalize serum interleukin-5 lev-
els, might be seen to contradict a previous report by Kelly
and associates reporting a significant reduction in serum
IL-5 levels in atopic asthmatics on inhaled glucocorticoid
treatment. However, our observations are consistent with
their finding from the same study subjects that inhaled
glucocorticoids did not reduce IL-5 production by periph-
eral blood mononuclear cells [10]; a similar lack of
response of IL-5 production by peripheral blood mono-
cytes to inhaled corticosteroids has been documented in
asthmatic children [9]. We cannot entirely discount the
possibility that inhaled glucocorticoids, in common with
oral glucocorticoids do reduce serum IL-5 level, as sequen-
tial IL-5 level measurement was not possible in this cross
sectional study. This issue can be best addressed by a lon-
gitudinal study.
Anti IL-5 but not anti-IgE has been shown to prevent air-
way inflammation [16]. Wang and associates have pro-
vided conclusive evidence using an animal model of
asthma that the main determinant of airway inflamma-
tion is the level of circulating IL-5 and not the IL-5 pro-
duced within the airways [5]. The importance of
circulating rather than airways IL-5 in the pathogenesis of
bronchial hyper responsiveness in asthmatic patients has
been documented by Van Rensen and associates [17].
Serum IL-5 levels according to the severity of asthma Figure 2
Serum IL-5 levels according to the severity of asthma. The 
box & whisker plot shows the median and interquartile val-
ues of serum IL-5 levels. The median serum IL-5 value in mild 
persistent and moderate persistent groups were significantly 
higher compared to normal controls(both p < 0.001 and < 
0.002). There was a trend for the median serum IL-5 to be 
higher in moderate persistent asthma than in mild persistent 
type of asthma (p = 0.13)
Serum IL-5 levels according to the treatment status Figure 3
Serum IL-5 levels according to the treatment status. The box 
& whisker plot shows the median and interquartile values of 
serum IL-5 levels. The median serum Il-5 values in patients on 
regular inhaled glucocorticoids and not on regular inhaled 
glucocorticoids were significantly higher compared to normal 
controls (p < 0.001 and < 0.002). There was no significant 
difference in the median serum IL-5 levels between asthmat-
ics using and not using inhaled glucocorticoids (p = 0.69).BMC Pulmonary Medicine 2004, 4 http://www.biomedcentral.com/1471-2466/4/2
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Hakonarson and associates have shown that human air-
way smooth muscle passively sensitized by serum from
atopic patients expresses receptors for IL-5. IL-5 has been
shown to elicit a cholinergic type of hyper responsiveness
in normal human bronchus and smooth muscle which
could be blocked by IL-5 receptor antibodies [18]. Finally,
administration of IL-5 antibody to a small number of
asthmatics has been shown to significantly reduce blood
and sputum eosinophil counts significantly [19]. Thus,
the raised serum IL-5 levels observed in our patients with
mild and moderate persistent asthma could have contrib-
uted to airway smooth muscle hyper responsiveness and
airway inflammation. Although administration of
inhaled glucocorticoids decreases airway inflammation
[10,20], it does not suppress IL-5 production by periph-
eral blood mononuclear cells [10]. The inability to control
or normalize the raised serum IL-5 levels by inhaled ster-
oids as observed in our patients, is in concordance with
this observation. Administration of agents that could con-
trol systemic Th2 responses may have a beneficial role in
the long-term management of asthma. In this regard
administration of antibodies against IL-5 [21,22] or IL-5
receptor [23], though debatable [24], may prove effective
novel therapeutic approaches to prevent the effect of ele-
vated systemic IL-5 levels in patients with atopic and non-
atopic asthma.
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